Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 7

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 7
---
 of the issued and outstanding Common Shares, all as more particularly described in the Circular and Proxy Statement (the 
 “Arrangement”);                                                                                                                                                                                                           |

| (2) | an ordinary resolution to approve, on an advisory and non-binding                                                                                                                        
 basis, the compensation to be paid or become payable to the Company’s named executive officers that is based on or otherwise relates to the Arrangement (the “Compensation Resolution”); |

| (3) | in the event that the Arrangement Resolution is not approved or the Arrangement is otherwise terminated, to                                                                                                                     
 consider, and if thought advisable, to pass, with or without variation, a special resolution pursuant to Section 308 of the QBCA to approve the voluntary liquidation (the “Liquidation”) and dissolution of the Company in the 
 event the Arrangement is terminated (the “Liquidation Resolution”);                                                                                                                                                             |

| (4) | in the event that the Arrangement Resolution is not approved or the Arrangement is otherwise terminated, and to                                                                                                                
 consider, and if thought advisable, to pass, with or without variation, a special resolution pursuant to Section 325 of the QBCA to approve the appointment of KPMG LLP (“KPMG”) or, in the alternative, another liquidator of 
 nationally recognized experience, as the liquidator of the Company (the “Liquidator”) with authorization for the board of directors of the Company (the “Board”) to set the remuneration of the liquidator (the                
 “Liquidator Resolution”); and                                                                                                                                                                                                  |

| (5) | to transact such further or other business that may properly come before the Special Meeting or any adjournment 
 or postponement thereof.                                                                                        |

Specific details of the matters proposed to be put before the Special Meeting are set forth in the Circular and Proxy Statement that accompanies this Notice of Special Meeting of Shareholders.

During the Special Meeting’s live webcast, Registered Shareholders and duly appointed
proxy holders will be able to participate, vote, and submit questions. Non-registered Shareholders who have not appointed themselves as proxy holders will be able to attend the Special Meeting as guests, but
guests will not be able to vote at the Special Meeting. See “Attending and Participating in the Special Meeting” for further instructions in the Circular and Proxy Statement. As noted above, the Special Meeting will be a virtual
meeting, which will be conducted exclusively on the internet. There will not be a physical meeting location, and Shareholders will not be